Equities analysts expect REDHILL BIOPHAR/S (NASDAQ:RDHL) to post ($0.32) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for REDHILL BIOPHAR/S’s earnings, with estimates ranging from ($0.33) to ($0.30). REDHILL BIOPHAR/S posted earnings per share of ($0.52) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.5%. The company is expected to announce its next quarterly earnings report on Thursday, August 29th.
On average, analysts expect that REDHILL BIOPHAR/S will report full year earnings of ($1.30) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.10). For the next year, analysts forecast that the company will report earnings of ($0.73) per share, with EPS estimates ranging from ($0.90) to ($0.40). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow REDHILL BIOPHAR/S.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.98 million. REDHILL BIOPHAR/S had a negative return on equity of 97.62% and a negative net margin of 506.47%.
Several analysts have recently issued reports on RDHL shares. WBB Securities raised REDHILL BIOPHAR/S from a “speculative buy” rating to a “buy” rating and set a $17.00 target price on the stock in a report on Tuesday, March 12th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of REDHILL BIOPHAR/S in a report on Wednesday, February 27th. Finally, Zacks Investment Research raised REDHILL BIOPHAR/S from a “sell” rating to a “hold” rating and set a $9.25 target price on the stock in a report on Tuesday, February 19th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. REDHILL BIOPHAR/S presently has an average rating of “Buy” and an average price target of $16.44.
Shares of RDHL traded up $0.04 during trading hours on Monday, hitting $7.64. 19,916 shares of the company were exchanged, compared to its average volume of 59,561. The firm has a market cap of $167.62 million, a P/E ratio of -4.49 and a beta of 1.69. REDHILL BIOPHAR/S has a fifty-two week low of $5.13 and a fifty-two week high of $11.49. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.99 and a current ratio of 4.09.
Several institutional investors and hedge funds have recently added to or reduced their stakes in RDHL. Renaissance Technologies LLC acquired a new stake in shares of REDHILL BIOPHAR/S during the 3rd quarter worth $1,226,000. Creative Planning grew its holdings in shares of REDHILL BIOPHAR/S by 73.9% during the 4th quarter. Creative Planning now owns 283,350 shares of the biotechnology company’s stock worth $1,573,000 after purchasing an additional 120,400 shares in the last quarter. ETF Managers Group LLC grew its holdings in shares of REDHILL BIOPHAR/S by 37.3% during the 4th quarter. ETF Managers Group LLC now owns 46,782 shares of the biotechnology company’s stock worth $260,000 after purchasing an additional 12,706 shares in the last quarter. CLARET ASSET MANAGEMENT Corp boosted its stake in REDHILL BIOPHAR/S by 42.1% in the fourth quarter. CLARET ASSET MANAGEMENT Corp now owns 67,522 shares of the biotechnology company’s stock valued at $375,000 after buying an additional 20,000 shares in the last quarter. Finally, Van ECK Associates Corp boosted its stake in REDHILL BIOPHAR/S by 42.1% in the fourth quarter. Van ECK Associates Corp now owns 10,787 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 3,195 shares in the last quarter. 38.72% of the stock is currently owned by institutional investors.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Recommended Story: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.